Condition: SLE - Systemic Lupus Erythematosus · Sponsor: Chengdu Ucello Biotechnology Co., Ltd.
The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the UCAR-T cell product.
This description comes directly from the study's public registry record.
Tao Wang, M.D. · +8613550080505 · cdjqzyywt@126.com
Xia zhao He, M.D. & Ph.D. · +8613350084795 · wangtaohhzx@hotmail.com
Always discuss trial participation with your own doctor first.
| Yancheng Third People's Hospital | Yancheng, Jiangsu, China | Recruiting |
| The General Hospital of Western Theater Command | Chengdu, Sichuan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07274059